

## V. Recommendations

- **Insulin glargine**

The **HTAC recommends the government financing of both insulin glargine 10mL vial (100 IU/ml) and 3mL pre-filled pen (100 IU/ml) through its inclusion in the PNF.** Insulin glargine has shown comparable efficacy and acceptable safety profiles in both T1DM and T2DM patients as compared to NPH insulin. Furthermore, the intervention when compared to NPH insulin has shown lower risk of severe hypoglycemia.

Although the cost-effectiveness of insulin glargine pen and vial cannot be ascertained in the Philippine setting based on the WHO review and its budget impact is high, the availability of numerous biosimilars in the market will enable the lowering of cost of the drug through competitive bidding.

- **Insulin detemir**

The **HTAC does not recommend the government financing and inclusion of insulin detemir pen (100IU/mL, 3mL prefilled pen) in the PNF.** Insulin detemir has shown comparable efficacy and acceptable safety profiles in both T1DM and T2DM patients as compared to NPH insulin. However, insulin detemir pen incurs a high budget impact. Additionally, since there is no biosimilar competitor, it is less likely to have a low bidding price.